367258-43-3

Basic information

• Product Name: Glycine, N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, phenylmethyl ester
• CAS NO: 367258-43-3
• Molecular Formula: C20H30N2O6
• Molecular Weight: 394.468
• Mol File: 367258-43-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Glycine, N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, phenylmethyl ester(367258-43-3)
• EPA Substance Registry System: Glycine, N-[3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, phenylmethyl ester(367258-43-3)

Safety Data

• Hazardous Substances Data: 367258-43-3(Hazardous Substances Data)

Upstream product

• 166196-05-0 3-amino-2-hydroxyhexanoic acid 
• 367258-42-2 2-hydroxy-3-nitrohexanoic acid 
• 166196-06-1 3-tert-butoxycarbonylamino-2-hydroxyhexanoic acid 
• 1738-68-7 Gly-OBz 
• 2462-31-9 benzyl 2-aminoacetate hydrochloride 

Downstream Products

• 371111-11-4 (S)-(2-{3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid benzyl ester 
• 371111-93-2 (S)-(2-{3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetylamino)-phenyl-acetic acid benzyl ester 
• 371110-93-9 (S)-(2-{3-[((9S,12S)-12-Cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[17.2.2.1^3,7]tetracosa-1⁽²²⁾,3,5,7⁽²⁴⁾,19⁽²³⁾,20-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371111-53-4 [12S,9S]-(2-{3-[(12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[17.2.2.1^3,7]tetracosa-1⁽²²⁾,3⁽²⁴⁾,4,6,19⁽²³⁾,20-hexaene-9-carbonyl)amino]-2-hydroxyhexanoylamino}acetylamino)-[S]-phenylacetic acid tert-butyl ester 
• 371110-91-7 (S)-(2-{3-[((9S,12S)-12-Cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[16.2.2.1^3,7]tricosa-1⁽²¹⁾,3,5,7⁽²³⁾,18⁽²²⁾,19-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371111-48-7 [12S,9S]-(2-{3-[(12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[16.2.2.1^3,7]tricosa-1⁽²¹⁾,3⁽²³⁾,4,6,18⁽²²⁾,19-hexaene-9-carbonyl)amino]-2-hydroxyhexanoylamino}acetylamino)phenylacetic acid tert-butyl ester 
• 371111-13-6 {3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetic acid benzyl ester 
• 371111-95-4 {3-[((9S,12S,15S)-15-tert-Butoxycarbonylamino-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-hydroxy-hexanoylamino}-acetic acid benzyl ester 
• 371110-87-1 (S)-(2-{3-[((9S,12S)-12-Cyclohexyl-11,14-dioxo-2-oxa-10,13-diaza-tricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3,5,7⁽²²⁾,17⁽²¹⁾,18-hexaene-9-carbonyl)-amino]-2-oxo-hexanoylamino}-acetylamino)-phenyl-acetic acid tert-butyl ester 
• 371111-45-4 [12S,9S]-(2-{3-[(12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[15.2.2.1^3,7]docosa-1⁽²⁰⁾,3⁽²²⁾,4,6,17⁽²¹⁾,18-hexaene-9-carbonyl)amino]-2-hydroxyhexanoylamino}acetylamino)-[S]-phenylacetic acid tert-butyl ester 
• 393581-55-0 [2-(3-tert-butoxycarbonylamino-2-hydroxy-hexanoylamino)-acetylamino]-phenyl-acetic acid benzyl ester 
• 873676-55-2 C₄₅H₅₉N₅O₁₁ 
• 873676-52-9 C₄₅H₅₉N₅O₁₁ 
• 368871-34-5 C₄₅H₆₁N₅O₁₁ 

Relevant articles and documents

Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease

The NS3 protease of hepatitis C virus (HCV) has emerged as one of the best characterized targets for next-generation HCV therapy. The tetrapeptide 1 and pentapeptide 2 are α-ketoamide-type HCV serine protease inhibitors with modest potency. We envisioned

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection

Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-α or polyethylene glycol (PEG)-interferon-α alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.

Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease

The limited efficacy and considerable side effects of currently available therapies for the treatment of hepatitis C virus (HCV) infection have prompted significant efforts toward the development of safe and effective new therapeutics. The pentapeptide α-